Contested and Open Cases

Bacteriophages were explored as antibacterial agents before antibiotics dominated Western medicine. Interest has returned because antimicrobial resistance creates infections where standard drugs may fail. Phage therapy has compassionate-use examples, research centers, and clinical trials, including difficult-to-treat infection studies registered at ClinicalTrials.gov.

The contested status comes from specificity and standardization. Phages can be highly strain-specific, manufacturing and matching can be complex, and a successful rescue case is not the same as broad evidence for routine use. This is a credible re-emerging field, not a universal antibiotic replacement.

Low-dose naltrexone has a strong internet life because it is inexpensive, off-patent, and used for conditions where patients often feel underserved. Mechanistic arguments around glial cells and inflammation are plausible enough to justify research. But plausibility is not the same as settled efficacy.

Recent reviews show why the case belongs here rather than in the vindicated archive. Some small studies and condition-specific reports are encouraging, while broader evidence remains inconsistent and sometimes negative for chronic pain outcomes. The right conclusion is "study carefully," not "hidden cure."

Vitamin D has an obvious appeal: it is essential, common, cheap, and connected to immune function. That makes it a magnet for broad prevention claims. The evidence is more modest. A 2026 Cochrane review in young children found vitamin D may slightly reduce the proportion needing a doctor or hospital visit for acute respiratory infections, but probably does not reduce how often each child visits, and higher doses probably do not improve those outcomes.

This is not a suppression story. It is a measurement story. Effects may differ by baseline deficiency, dose, age, and outcome definition. The claim should be sized to the evidence.

Hyperbaric oxygen therapy has plausible physiology: oxygen delivery, tissue injury, swelling, and secondary brain damage are real concerns after traumatic brain injury. Cochrane's review found small trial evidence suggesting possible mortality and coma-scale effects, but also found no evidence that survivors had improved quality of life and concluded routine use could not be justified from the available evidence.

That is exactly what "contested" means. There is enough to ask better questions, not enough to market certainty. People should be especially wary when a therapy with complex equipment and real risks is advertised far beyond the populations studied.